For Q3 of FY2026 (consolidated), revenue was 2,991,382 million yen, operating income was 947,710 million yen, and profit attributable to owners of the parent for the quarter was 618,892 million yen, representing a substantial change YoY. Full-year forecasts were revised to revenue of 3,903,000 million yen, operating income of 1,041,000 million yen, and profit of 662,000 million yen. Adjusted operating income on a constant currency basis is expected to be 1,028,000 million yen. Comparative presentation reflects deconsolidation of the pharmaceutical business as a discontinued operation. Earnings presentation materials have been published.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2914","jir_company_name":"Japan Tobacco Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2914-20261029-01.pdf","jir_short_summary":"For Q3 of FY2026 (consolidated), revenue was 2,991,382 million yen, operating income was 947,710 million yen, and profit attributable to owners of the parent for the quarter was 618,892 million yen, representing a substantial change YoY. Full-year forecasts were revised to revenue of 3,903,000 million yen, operating income of 1,041,000 million yen, and profit of 662,000 million yen. Adjusted operating income on a constant currency basis is expected to be 1,028,000 million yen. Comparative presentation reflects deconsolidation of the pharmaceutical business as a discontinued operation. Earnings presentation materials have been published.","jir_summary":"### Overview of Results\nFor Q3 of FY2026 (consolidated), revenue was 2,991,382 million yen (YoY +13.6%) and operating income was 947,710 million yen (YoY +24.2%), showing steady growth. Meanwhile, profit attributable to owners of the parent for the period was 618,892 million yen, a significant decline YoY. The statements adopt a presentation that reflects the pharmaceutical business as a discontinued operation, and comparisons on a continuing-operations basis show growth. The full-year forecast is revenue of 3,903,000 million yen, operating income of 1,041,000 million yen, and profit of 662,000 million yen, with adjusted operating income on a constant currency basis estimated at 1,028,000 million yen.\n\n### Outlook and Impact for Investors\nThe company targets mid to high single digit average annual growth in adjusted operating income on a constant currency basis as a medium- to long-term objective. Taking into account the impact of comparative presentation due to the deconsolidation of the pharmaceutical business, the company will focus on strengthening earnings power of continuing operations. As of the end of September 2026, cash and cash equivalents were 8,873 million yen, and financial soundness has improved. Investors should note potential impacts such as installment payments related to settlement costs, but earnings presentation materials have been released; therefore, it is appropriate for investors to evaluate performance primarily on a continuing-operations basis.","jir_financial_highlights":"Revenue: 2,991,382 million yen (Year-over-Year (YoY) +13.6%)\nOperating Income: 947,710 million yen (Year-over-Year (YoY) +24.2%)\nProfit Attributable to Owners of Parent (Quarter): 618,892 million yen (Year-over-Year (YoY) -30.6%)\nNet Cash Provided by Operating Activities (Summary Quarterly Consolidated Cash Flow): 7,312 million yen (Increase Year-over-Year)","jir_category":"","jir_hashtags":"#JapanTobacco, #Earnings, #CurrencyImpact, #ContinuingOperations, #FinancialPosition","jir_key_figures":"Revenue: 2,991,382 million yen\nOperating Income: 947,710 million yen\nProfit Attributable to Owners of Parent (Quarter): 618,892 million yen","jir_meta_title":"Japan Tobacco Inc. Q3 FY2026 Financial Summary | Revenue and Profit Trends","jir_meta_description":"Summary of Japan Tobacco Inc.'s Q3 FY2026 financial results: revenue 2,991,382 million yen, operating income 947,710 million yen, profit 618,892 million yen. Full-year outlook: revenue 3,903,000 million yen, operating income 1,041,000 million yen, profit 662,000 million yen. Includes discussion of discontinued-operation impacts.","jir_og_title":"Japan Tobacco Inc. Releases Q3 Financial Results | Revenue & Profit Trends","jir_og_description":"Summary of Japan Tobacco Inc.'s Q3 FY2026 results. Solid revenue growth on a continuing-operations basis, while noting impacts from discontinued pharmaceutical operations. Full-year outlook provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6848,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136578","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n